Duncker Streett & Co. Inc. lessened its stake in shares of Stryker Co. (NYSE:SYK) by 3.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,766 shares of the medical technology company’s stock after selling 971 shares during the quarter. Stryker makes up approximately 1.3% of Duncker Streett & Co. Inc.’s holdings, making the stock its 12th largest holding. Duncker Streett & Co. Inc.’s holdings in Stryker were worth $6,763,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of the stock. Clarius Group LLC increased its position in Stryker by 1.3% during the 1st quarter. Clarius Group LLC now owns 3,001 shares of the medical technology company’s stock worth $731,000 after purchasing an additional 38 shares in the last quarter. Essex Savings Bank grew its holdings in Stryker by 0.7% in the 1st quarter. Essex Savings Bank now owns 5,449 shares of the medical technology company’s stock valued at $1,323,000 after buying an additional 39 shares during the period. Tower View Investment Management & Research LLC grew its holdings in Stryker by 9.0% in the 4th quarter. Tower View Investment Management & Research LLC now owns 510 shares of the medical technology company’s stock valued at $125,000 after buying an additional 42 shares during the period. Van ECK Associates Corp grew its holdings in Stryker by 0.5% in the 4th quarter. Van ECK Associates Corp now owns 8,681 shares of the medical technology company’s stock valued at $2,127,000 after buying an additional 42 shares during the period. Finally, BBR Partners LLC grew its holdings in Stryker by 3.4% in the 4th quarter. BBR Partners LLC now owns 1,272 shares of the medical technology company’s stock valued at $312,000 after buying an additional 42 shares during the period. Hedge funds and other institutional investors own 71.46% of the company’s stock.
In related news, CFO Glenn S. Boehnlein sold 2,000 shares of the stock in a transaction on Monday, March 1st. The stock was sold at an average price of $246.01, for a total value of $492,020.00. Following the completion of the transaction, the chief financial officer now owns 12,321 shares in the company, valued at approximately $3,031,089.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP M Kathryn Fink sold 4,000 shares of the stock in a transaction on Thursday, April 8th. The shares were sold at an average price of $250.00, for a total value of $1,000,000.00. The disclosure for this sale can be found here. Company insiders own 6.80% of the company’s stock.
SYK has been the subject of a number of research reports. Oppenheimer boosted their target price on Stryker from $240.00 to $273.00 in a report on Wednesday, April 28th. JPMorgan Chase & Co. boosted their target price on Stryker from $245.00 to $265.00 and gave the stock an “overweight” rating in a report on Tuesday, March 2nd. Morgan Stanley boosted their target price on Stryker from $265.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday. Deutsche Bank Aktiengesellschaft boosted their price target on Stryker from $251.00 to $285.00 and gave the stock a “buy” rating in a research report on Wednesday, April 28th. Finally, Cowen boosted their price target on Stryker from $255.00 to $279.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 28th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $261.59.
NYSE:SYK opened at $263.10 on Tuesday. The business’s 50-day moving average price is $249.13 and its 200 day moving average price is $238.13. The firm has a market cap of $99.12 billion, a P/E ratio of 57.07, a PEG ratio of 2.79 and a beta of 0.87. Stryker Co. has a 52-week low of $171.75 and a 52-week high of $268.04. The company has a quick ratio of 2.15, a current ratio of 2.89 and a debt-to-equity ratio of 0.92.
Stryker (NYSE:SYK) last released its earnings results on Monday, April 26th. The medical technology company reported $1.93 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.99 by ($0.06). Stryker had a return on equity of 20.94% and a net margin of 12.35%. The firm had revenue of $3.95 billion for the quarter, compared to analyst estimates of $3.94 billion. During the same period in the previous year, the firm earned $1.84 earnings per share. Stryker’s revenue was up 10.2% on a year-over-year basis. Sell-side analysts expect that Stryker Co. will post 7.18 EPS for the current year.
Stryker Company Profile
Stryker Corp. engages in the provision of medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The MedSurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling and reprocessed medical devices.
See Also: Holder of Record
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.